Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function

Sponsor
Novo Nordisk A/S
Study ID
NCT01507389
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • liraglutide — DRUG
    Single dose of 0.75 mg injected subcutaneously (under the skin)

Study Details

This trial is conducted in Europe. The aim of this trial is to investigate liraglutide in subjects with mild, moderate and severe degrees of hepatic impairment compared with subjects with normal hepatic function.

Key Dates

Start date
Mar 31, 2006
Status verified
Dec 2014
Primary completion
Jun 30, 2006
Completion
Jun 30, 2006

Study Design

Enrollment
24 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Mild
  • Experimental: Moderate
  • Experimental: Severe
  • Experimental: Normal

Primary Outcome Measure

Area under the Curve (0-infinity)

Related Studies